Beta Glucan in Treatment of Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Diseases (IBD): Ulcerative Colitis (UC) and Crohn's Disease (CD)

Preview this chapter:

Beta Glucan in Treatment of Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Diseases (IBD): Ulcerative Colitis (UC) and Crohn's Disease (CD), Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815039238/chapter-9-1.gif

<div&gt;Since ancient times, the healing properties of fungi have been used in the&lt;/div&gt;<div&gt;treatment of many health problems such as hypertension, diabetes, allergies, cancer,</div&gt;<div&gt;atherosclerosis, digestive system disorders and inflammation. Inflammatory bowel&lt;/div&gt;<div&gt;diseases are a very serious health problem that significantly reduces a person's quality&lt;/div&gt;<div&gt;of life. Regarding immune-mediated inflammatory diseases, two of the most common&lt;/div&gt;<div&gt;types of inflammatory bowel disease are Crohn's disease (CD) and ulcerative colitis&lt;/div&gt;<div&gt;(UC). Levels of C reactive protein (CRP), neutrophil elastase, leukocyte esterase,</div&gt;<div&gt;interleukin 1ß (IL-1ß), interleukin receptor 1 antagonist, tumor necrosis factor (TNF),</div&gt;<div&gt;and eosinophilic cationic protein (ECP) biomarkers observed in the body in&lt;/div&gt;<div&gt;inflammatory bowel diseases. It is reduced by giving the body β-glucan. At the same&lt;/div&gt;<div&gt;time, the percentage of lymphocytes was decreased, and pathways for cytokine and&lt;/div&gt;<div&gt;chemokine marking were developed. This review focuses on the therapeutic effect and&lt;/div&gt;<div&gt;mechanism of β-glucan content derived from fungi, yeasts, and other organic sources&lt;/div&gt;<div&gt;on inflammatory bowel disease (IBD) such as CD and UC, and irritable bowel&lt;/div&gt;<div&gt;syndrome (IBS). </div&gt;